share_log

Jiangsu Recbio Technology Co., Ltd.'s (HKG:2179) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 15% Last Week

Jiangsu Recbio Technology Co., Ltd.'s (HKG:2179) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 15% Last Week

江苏瑞科生物科技有限公司's (HKG: 2179) 最大的所有者是散户投资者,他们在上周股价飙升15%后变得更富有
Simply Wall St ·  03/26 20:03

Key Insights

关键见解

  • Jiangsu Recbio Technology's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • The top 6 shareholders own 51% of the company
  • Institutional ownership in Jiangsu Recbio Technology is 20%
  • 江苏瑞科生物科技拥有大量散户投资者的所有权,这表明关键决策受广大公众股东的影响
  • 前6名股东拥有公司51%的股份
  • 江苏瑞科生物科技的机构所有权为20%

If you want to know who really controls Jiangsu Recbio Technology Co., Ltd. (HKG:2179), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are retail investors with 26% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道谁真正控制着江苏瑞科生物技术有限公司(HKG: 2179),那么你必须看看其股票登记处的构成。而持有最大份额的群体是拥有26%所有权的散户投资者。也就是说,如果股票上涨,该集团将受益最大(如果出现低迷,则损失最大)。

As a result, retail investors collectively scored the highest last week as the company hit HK$4.4b market cap following a 15% gain in the stock.

结果,散户投资者上周集体得分最高,该公司的市值在股价上涨15%后达到44亿港元。

In the chart below, we zoom in on the different ownership groups of Jiangsu Recbio Technology.

在下图中,我们放大了江苏瑞科生物科技的不同所有权群体。

ownership-breakdown
SEHK:2179 Ownership Breakdown March 27th 2024
SEHK: 2179 所有权明细 2024 年 3 月 27 日

What Does The Institutional Ownership Tell Us About Jiangsu Recbio Technology?

关于江苏瑞科技,机构所有权告诉我们什么?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常见指数的回报进行比较。因此,他们通常会考虑收购相关基准指数中包含的大型公司。

We can see that Jiangsu Recbio Technology does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Jiangsu Recbio Technology, (below). Of course, keep in mind that there are other factors to consider, too.

我们可以看到,江苏瑞科生物科技确实有机构投资者;他们持有该公司很大一部分股票。这可能表明该公司在投资界具有一定程度的信誉。但是,最好谨慎地依赖机构投资者所谓的验证。他们有时也会弄错。如果两个大型机构投资者试图同时抛售股票,股价大幅下跌的情况并不少见。因此,值得查看江苏瑞科生物科技过去的收益轨迹(见下文)。当然,请记住,还有其他因素需要考虑。

earnings-and-revenue-growth
SEHK:2179 Earnings and Revenue Growth March 27th 2024
SEHK: 2179 2024 年 3 月 27 日的收益和收入增长

Jiangsu Recbio Technology is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is Taizhou Yuangong Technology Partnership (Limited Partnership) with 17% of shares outstanding. For context, the second largest shareholder holds about 8.7% of the shares outstanding, followed by an ownership of 7.8% by the third-largest shareholder.

江苏瑞科生物科技不归对冲基金所有。从我们的数据来看,我们可以看到最大股东是台州元工科技合伙企业(有限合伙企业),已发行股份的17%。就背景而言,第二大股东持有约8.7%的已发行股份,其次是第三大股东持有7.8%的所有权。

We did some more digging and found that 6 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我们做了进一步的挖掘,发现大股东中有6人约占登记册的51%,这意味着除了较大的股东外,还有一些较小的股东,从而在一定程度上平衡了彼此的利益。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is some analyst coverage of the stock, but it could still become more well known, with time.

研究机构所有权是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪也可以达到同样的目的。有一些分析师对这只股票的报道,但随着时间的推移,它仍可能变得更加广为人知。

Insider Ownership Of Jiangsu Recbio Technology

江苏瑞科生物科技的内部所有权

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

不同国家对内部人士的定义可能略有不同,但董事会成员总是计算在内。公司管理层对董事会的回答,董事会应代表股东的利益。值得注意的是,有时高层管理人员自己也在董事会中。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。

We can report that insiders do own shares in Jiangsu Recbio Technology Co., Ltd.. In their own names, insiders own HK$142m worth of stock in the HK$4.4b company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

我们可以报告,内部人士确实拥有江苏瑞科生物科技有限公司的股份。内部人士以自己的名义拥有这家44亿港元公司价值1.42亿港元的股票。这至少显示出一定的对齐性。你可以点击这里查看这些内部人士是否在买入或卖出。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 26% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

包括散户投资者在内的公众拥有该公司26%的股份,因此不容忽视。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。

Private Equity Ownership

私募股权所有权

With an ownership of 22%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私募股权公司拥有22%的所有权,能够在制定以价值创造为重点的企业战略方面发挥作用。有时我们会看到私募股权长期存在,但总的来说,它们的投资期限较短,而且顾名思义,对上市公司的投资并不多。一段时间后,他们可能会考虑出售资金并将其重新部署到其他地方。

Private Company Ownership

私人公司所有权

It seems that Private Companies own 11%, of the Jiangsu Recbio Technology stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

私人公司似乎拥有江苏瑞科生物科技11%的股份。私营公司可能是关联方。有时,内部人士通过控股私营公司而对上市公司拥有权益,而不是以个人身份拥有权益。尽管很难得出任何宽泛的结论,但值得注意的是,这是一个需要进一步研究的领域。

Next Steps:

后续步骤:

It's always worth thinking about the different groups who own shares in a company. But to understand Jiangsu Recbio Technology better, we need to consider many other factors. For instance, we've identified 4 warning signs for Jiangsu Recbio Technology (2 make us uncomfortable) that you should be aware of.

拥有公司股份的不同群体总是值得考虑的。但是,要更好地了解江苏瑞科技,我们需要考虑许多其他因素。例如,我们已经确定了江苏瑞科生物科技的4个警告信号(2个让我们感到不舒服),你应该注意这些信号。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但归根结底,决定这家企业所有者的表现的是未来,而不是过去。因此,我们认为最好看一下这份免费报告,该报告显示了分析师是否预测了更光明的未来。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发